InvestorsHub Logo
Followers 5
Posts 430
Boards Moderated 0
Alias Born 11/05/2013

Re: None

Wednesday, 03/25/2015 8:10:43 AM

Wednesday, March 25, 2015 8:10:43 AM

Post# of 92948
Comparing OCAT to another Biotech, Reveals Complete Ignorance

of what Ocata has achieved, and what's going on here.

Ocata has done two essential things that sets it apart
from anything before it.

First, Ocata has discovered a way to manufacture RPE cells identical to the cells already in your body. For this to fail in
the future, they would have to 'somehow?' un-discover this.

And this is simply impossible. You cannot un-discover
anything!


And these are not stem cells any longer, so there is no tumor risk. Not stem cells, RPE cells. To talk about tumors is
ignorance and scare talk, that ignores phase 1 data.

SECOND, Ocata has developed a technique for transplanting
these RPE cells into the eye and have them take hold and
flourish and rebuild the bottom layer of the retina. For this
to fail they would have to un-learn what they already know.
And this is not possible.

Let Dr. Anglade explain it.
RoadShow Slide 21
Dr. Anglade: Talking about people with
macular degeneration(Partial Blindness):
Our proposition for these patients is to take a suspension of the pigment epithelia cells and inject them right under the retina.

They[the RPE cells] go and find a place to begin functioning and ultimately...re-establish those connections that are necessary for vision. And allow the patients to re-establish vision.

...Up till now it's been technically challenging to do this, almost essentially impossible. But the first hurdle was to be able to do this, and it's been done.



So what Ocata has done here amounts to discovery and
technique.

THIS IS NOT LIKE ANY OTHER BIOTECH COMPANY BEFORE!

You cannot compare Ocata to anything else in existence.
Because it's a completely new discovery.

The pitter-patter about phase 2 and phase 3 is just so
much drivel. With a phase 2 pivotal, I don't think there
will even be a phase 3.

It's certainly not like a drug, in spite of the FDAs regulatory approach. There's no worry about RPE cells being toxic
to the liver or kidney.
You already have RPE cells in your body!

And it's not comparable to a risky heart transplant.
The RPE layer of the retina is not a major or essential
component of your body. Even if RPE therapy fails
once in while, so what, the patient has lost nothing.
He simply hasn't gained anything.

This is key! This certainly won't work every time. But
who cares? Some patient's eyes will undoubtedly be
un-repairable. But this does NOT take anything away
from RPE therapy!

After phase 1, there is no down side here!

The market will figure this out, eventually.

"Those who are enlightened before the others. Are
condemned to pursue that light. In spite of others."
Christopher Columbus.



This is kind of appropriate.
www.youtube.com/watch?v=Q0iqg2UanEc

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.